PLX3397

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Melanoma

Conditions

Melanoma

Trial Timeline

Jan 31, 2017 → Oct 11, 2024

NCT ID

NCT02975700

About PLX3397

PLX3397 is a pre-clinical stage product being developed by Daiichi Sankyo for Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02975700. Target conditions include Melanoma.

What happened to similar drugs?

4 of 20 similar drugs in Melanoma were approved

Approved (4) Terminated (2) Active (14)

✅dabrafenib + trametinibNovartisApproved

✅ZelborafRocheApproved

✅Nivolumab + RelatlimabBristol Myers SquibbApproved

✅Fibrin Sealant (Tisseel) used in the Experimental Arm.BaxterApproved

❌Tasisulam-sodium + PaclitaxelEli LillyPhase 3

🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02975700	Pre-clinical	Completed	Jan 31, 2017	Oct 11, 2024	Melanoma
NCT01499043	Phase 2	Terminated	May 25, 2012	Mar 11, 2013	Prostate Cancer
NCT01349036	Phase 2	Terminated	Dec 3, 2011	Nov 5, 2013	Recurrent Glioblastoma
NCT01217229	Phase 2	Completed	Mar 3, 2011	Apr 26, 2012	Hodgkin Lymphoma
NCT01004861	Phase 1	Completed	Oct 1, 2009	Oct 25, 2018	Solid Tumor

Competing Products

20 competing products in Melanoma

See all competitors

Product	Company	Stage	Hype Score
mRNA-4157 + Pembrolizumab	Merck	Phase 2	39
AVT32-DRL_PB + Keytruda	Dr. Reddy's Laboratories	Phase 1	33
Binimetinib Oral Tablet	Biotrial	Phase 1	15
Tasisulam-sodium + Paclitaxel	Eli Lilly	Phase 3	32
[203Pb]VMT01 + [212Pb]VMT01 + Nivolumab	Perspective Therapeutics	Phase 1/2	33
[203Pb]VMT01 + [68Ga]VMT02	Perspective Therapeutics	Phase 1	23
FYB206 + Keytruda	Formycon AG	Phase 1	23
PLX3397 + Pembrolizumab	Daiichi Sankyo	Phase 1/2	24
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	39
DS-8273a + Nivolumab	Daiichi Sankyo	Phase 1	29
PLX3397 + vemurafenib	Daiichi Sankyo	Phase 1	21
enfortumab vedotin + pembrolizumab	Astellas Pharma	Phase 2	42
CP-461	Astellas Pharma	Phase 2	27
YM155	Astellas Pharma	Phase 2	35
YM155 + Docetaxel	Astellas Pharma	Phase 2	35
Denileukin diftitox	Eisai	Phase 2	35
E7080	Eisai	Phase 1	29
lenvatinib + pembrolizumab	Eisai	Phase 2	35
MORAb-004 (monoclonal antibody)	Eisai	Phase 2	35
Pembrolizumab + Lenvatinib	Eisai	Phase 2	39